Bristol Myers Squibb partnered with Anthropic to deploy Claude AI across global operations, aiming to accelerate drug discovery and development through enterprise-wide integration. The platform is intended to serve as a shared intelligence system for more than 30,000 employees across research, clinical development, manufacturing, and commercial functions. BMS said the initiative goes beyond chatbot-style use, targeting more agentic workflows embedded in day-to-day operations. Priority areas include software acceleration via Claude Code, trial documentation automation, and extracting predictive insights from BMS scientific and molecular data to support target identification and optimization across multiple therapeutic areas. —